US equities |
INTC $119.13 ▼-0.17% MU $1,074.89 ▲+0.00% SNDK $1,719.99 ▲+0.00% NVDA $233.95 ▲+0.00% SPCX $158.96 ▲+0.00% AMD $633.91 ▲+0.00% WDC $415.29 ▲+0.00% MSTR $160.01 ▲+0.00%
FinancialContent

Eton Pharmaceuticals, Inc. - Common Stock (NQ:ETON)

55.36 UNCHANGED
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eton Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Eton Pharmaceuticals Announces Positive Pivotal Clinical Study Results for Product Candidate ET-600
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Rocket Companies, Novo Nordisk And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Eton Pharmaceuticals to Host Virtual Investor Day and Release Fourth Quarter Earnings Results on March 18, 2025
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
The Analyst Verdict: Eton Pharmaceuticals In The Eyes Of 5 Experts ↗
 
Via Benzinga
News headline image
Analyst Expectations For Eton Pharmaceuticals's Future ↗
 
Via Benzinga
News headline image
Eton Pharmaceuticals Announces Commercial Launch of Galzin® (zinc acetate) Capsules
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Expands Patent Portfolio with Issuance of New U.S. Patent for ET-600
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Announces Extension of PDUFA Goal Date for ET-400
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Advances Its Commitment to Rare Disease with the Acquisition of Galzin®
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Earnings Scheduled For November 12, 2024 ↗
 
Via Benzinga
News headline image
Earnings Outlook For Eton Pharmaceuticals ↗
 
Via Benzinga
News headline image
Critical Insights From Eton Pharmaceuticals Analyst Ratings: What You Need To Know ↗
 
Via Benzinga
News headline image
Eton Pharmaceuticals Closes Acquisition of Increlex® (mecasermin injection)
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Announces Final Readout of PKU GOLIKE® Clinical Trial
Clinical Trial Demonstrates Clinical and Statistical Improvement in Metabolic Control During Prolonged Fasting in PKU Patients - Results Expected to Promote Awareness and Adoption of PKU GOLIKE® 
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Announces Acquisition of U.S. Rights to Amglidia (Glyburide Oral Suspension)
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
SWK Holdings Provides Portfolio Update
Via ACCESSWIRE
News headline image
Eton Pharmaceuticals Reports Third Quarter 2024 Financial Results
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals Awarded Second Patent for ET-400 (Hydrocortisone Oral Solution)
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
3 Stocks Insiders Are Buying Heavily In October 2024, And Why ↗
Should investors add these stocks on their watchlist? Insider buys suggest so. 
Via Talk Markets
News headline image
Domino's Pizza To Rally Over 38%? Here Are 10 Top Analyst Forecasts For Friday ↗
 
Via Benzinga
News headline image
Eton Pharmaceuticals, Inc to Acquire Increlex® (mecasermin injection) from Ipsen
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals to Participate at the H.C. Wainwright 26th Annual Global Investment Conference
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
ETON Stock Earnings: Eton Pharmaceuticals Misses EPS, Misses Revenue for Q2 2024 ↗
ETON stock results show that Eton Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Eton Pharmaceuticals Reports Second Quarter 2024 Financial Results
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
Eton Pharmaceuticals to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
SWK Holdings Highlights Recent Achievements and Provides Portfolio Update
Via ACCESSWIRE
News headline image
Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-400 (Hydrocortisone Oral Solution)
From Eton Pharmaceuticals
Via GlobeNewswire
News headline image
ETON Stock Earnings: Eton Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024 ↗
ETON stock results show that Eton Pharmaceuticals beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
< Previous 1 2 3 4 5 6 7 8 Next >